Allarity Therapeutics, Inc.
ALLR$15M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaBOSTON6 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Mar 15, 2027
45wMarket Overview
Stock performance and key metrics
ALLR News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
2X-121
Advanced Ovarian Cancer
PARP inhibitor 2X-121
Metastatic Breast Cancer
Irofulven
Metastatic Castration-Resistant Prostate Cancer Patients
LiPlaCis
Phase 1: Advanced or Refractory Solid Tumours
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
2X-121 | Phase 2 | Advanced Ovarian Cancer | - | - |
PARP inhibitor 2X-121 | Phase 2 | Metastatic Breast Cancer | - | - |
Irofulven | Phase 2 | Metastatic Castration-Resistant Prostate Cancer Patients | - | - |
LiPlaCis | Phase 2 | Phase 1: Advanced or Refractory Solid Tumours | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply